The good news and the bad news
==============================

In the past 100 years our grasp of the biology of cancer has come a very long way. We now have a working knowledge of how tumors initially form, grow and spread. Importantly, vast amounts of information about features distinguishing tumor from normal cells is being accumulated, resulting in frequent, major new insights into cancer biology.

The bad news is that translating this information into the development of new treatments, or even refining the use of the ones we already have, has been much less impressive. Clinicians will attest that cytotoxic chemotherapy regimens, developed with the limited biological information available at the time of their development, remain the mainstay of treatment for most cancers. There are a few high-profile examples of rationally and molecularly targeted therapies, but we need to do much better if we are to shift the entire pattern of treatment to drugs that have high potency but mild side effects.

A brief history of old-school and new age drug discovery
========================================================

Several articles have extensively reviewed the history of cancer drug development \[[@B1]\] and so here we will only pick out the salient points. It is widely accepted, although clouded by the secrecy of war \[[@B2]\], that the first tentative steps to treating cancer with drugs emanated from the observation that exposure to chemical warfare agents (\'poison gases\'), such as nitrogen mustards, could limit the proliferative nature of rapidly dividing lymphoid cells. Goodman and Gilman reasoned that this could translate into a therapeutic context and used the nitrogen mustard mustine to treat a patient with non-Hodgkin\'s lymphoma \[[@B3]\]. Around the same time, and building on the observation that the vitamin folic acid could stimulate acute lymphoblastic leukemia (ALL) cells, Farber used folate analogs such as aminopterin and then amethopterin (methotrexate) to treat ALL, in what is often heralded as the first \'rational\' drug development approach \[[@B4]\]. Burchenal, Hitchings and Elion used a similar approach to assess the potential of purine analogs, identifying 6-mercaptopurine (reviewed in \[[@B5]\]). The nitrogen mustards and folate and purine analogs were much later shown to interfere with DNA replication, in part explaining their anti-tumor activity. In contrast, the alkaloids of the Madagascar periwinkle, such as vincristine, originally identified in the 1950s in a screen for anti-diabetic drugs, block tumor cell division, and therefore proliferation, largely by inhibiting microtubule polymerization \[[@B6]\]. All these therapies remain in clinical use today.

Following the discovery of chemotherapeutics, the next significant advance came in the 1960s with the straightforward notion of combining drugs. The rationale for this came from the treatment of tuberculosis, for which antibiotics, each with a different mechanism of action, were more effective when used in combination. For cancer, it was considered that the development of resistance to a battery of agents used concurrently, rather than a single drug, was less likely. Using this approach, Holland, Freireich and Frei pioneered a combination of methotrexate and 6-mercaptopurine for treating children with ALL (reviewed in \[[@B7]\]). Today, most cancer chemotherapy regimens use this same paradigm.

Anti-hormone therapy has been spectacularly successful in the treatment of breast cancer. Tamoxifen, the most successful of these agents, was identified in the early 1960s as an estrogen receptor (ER) antagonist (more correctly, a selective estrogen receptor modulator). This drug, originally developed by Walpole\'s group at ICI as a potential contraceptive, showed its potential when initially trialed for breast cancer in 1971 \[[@B8]\]. Subsequent clinical trials have confirmed the utility of this drug in ERα-positive breast cancer patients and tamoxifen has now been given to millions of women and has saved countless lives.

The impact of biology on cancer drug development at this stage was limited; most therapies had been identified either by serendipity or had been selected primarily on the basis that they could limit cell division. However, in the 1970s and 1980s, the advent of gene manipulation and molecular genetic analysis changed the nature of biological research forever and with it the drug discovery and development process. Molecularly targeted therapies could now be contemplated, that is, drugs that were rationally designed or selected to inhibit the activity of specific molecules (Table [1](#T1){ref-type="table"}). If used in the right patient population - on tumors with specific molecular lesions - these therapies promised significant tumor selectivity. One of the most remarkable examples of the development of such a targeted therapy, to which biological research made a critical contribution, is that of imatinib (Gleevec; Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

###### 

Some examples of targeted therapies for cancer

  Drug                           Brand name   Drug target\*               Cancer types
  ------------------------------ ------------ --------------------------- -------------------------------------------------
  **In clinical use**                                                     
   Bevacizumab                   Avastin      VEGF                        Colorectal, non-small cell lung, breast, renal
                                                                          
   Bortezomib                    Velcade      Proteasome                  Myeloma, lymphoma
                                                                          
   Celecoxib                     Onsenal      COX2                        Familial adenomatous polyposis
                                                                          
   Erlotinib                     Tarceva                                  
                                                                          
   Gefitinib                     Iressa       EGFR                        Non-small cell, lung, colorectal, head and neck
                                                                          
   Cetuximab                     Erbitux                                  
                                                                          
   Panitumumab                   Vectibix                                 
                                                                          
   Imatinib                      Gleevec                                  
                                                                          
   Dasatinib                     Sprycel      BCR-ABL, cKIT, PDGFR        Leukemia, gastrointestinal
                                                                          
   Nilotinib                     Tasigna                                  
                                                                          
   Methotrexate                               DHFR                        Multiple cancer types
                                                                          
   RAD001                        Certican     mTOR                        Renal
                                                                          
   Temirolimus                   Toricel                                  
                                                                          
   Sorafenib                     Nexavar      VEGFR, RAF, cKIT, PDGFR     Renal, hepatic
                                                                          
   Sunitinib                     Sutent                                   
                                                                          
   Topotecan                     Hycamtin     Topoisomerase I             Multiple cancer types
                                                                          
   Irinotecan                    Camptosar                                
                                                                          
   Trastuzumab                   Herceptin    ERBB2                       Breast
                                                                          
   Lapatinib                     Tykerb       HER2, EGFR                  Breast
                                                                          
   Tamoxifen                     Nolvadex     ERα                         Breast
                                                                          
   Exemestane                    Aromasin                                 
                                                                          
   Anastrozole                   Arimidex     Aromatase cytochrome P450   Breast
                                                                          
   Letrozole                     Femara                                   
                                                                          
   Rituximab                     MabThera     CD20                        Lymphoma
                                                                          
   Tositumomab                   Bexxar                                   
                                                                          
  **In development**                                                      
   17AAG                                      HSP90                       
                                                                          
   ABT-737, ABT-263, Obatoclax                BCL-XL, BCL-2               
                                                                          
   Alvocidib                                  CDKs                        
                                                                          
   Olaparib, AG014699                         PARP1/2                     
                                                                          
   BEZ235                                     PI3K                        
                                                                          
   GRN163L                                    hTERT                       
                                                                          
   Mapatumumab                                TRAIL Receptor              
                                                                          
   Nutlin-3                                   MDM2                        
                                                                          
   PLX4032                                    BRAF                        
                                                                          
   GDC-0449                                   SMO                         
                                                                          
   PF-0477736                                 CHK1                        

\*Target abbreviations: BCL-2, anti-apoptotic protein BCL-2; BCL-XL, anti-apoptotic protein BCL extra large; BCR-ABL, fusion protein of breakpoint cluster region and tyrosine kinase ABL1; BRAF, protein tyrosine kinase BRAF; CD20, B-cell phosphoprotein CD20; CDKs, cyclin-dependent kinases; CHK1, serine/threonine kinase CHK1; cKIT, tyrosine kinase c-KIT; COX2, cyclooxygenase 2; DHFR, dihydrofolate reductase; EGFR, epidermal growth factor receptor; ERα, estrogen receptor α; HER2, human epidermal growth factor receptor 2; HSP90, heat shock protein 90; hTERT, telomerase reverse transcriptase; MDM2, murine double minute 2; mTOR, mammalian target of rapamycin; PARP1/2, poly(ADP-ribose) polymerase 1/2; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol 3-kinase; RAF, small GTPase RAF; SMO, Smoothened; TRAIL receptor, TNF-related apoptosis-inducing ligand receptor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.

![**Targeted therapy for chronic myelogenous leukemia (CML)**. **(a)**One of the more common molecular changes in hematopoietic cells from CML patients is a reciprocal translocation (swap) of DNA between the long arms of chromosomes 9 and 22. This translocation forms the \'fusion\' gene *BCR-ABL*, which encodes a constitutively active ABL kinase. **(b)**The constitutive activity of BCR-ABL in hematopoietic CML cells drives several candidate oncogenic signaling pathways. Hematopoietic cells in CML patients are \'addicted\' to BCR-ABL signaling such that BCR-ABL inhibition impairs their viability. **(c)**Tyrosine kinases such as ABL and BCR-ABL have well defined catalytic domains that bind ATP and use its phosphate moiety to post-translationally modify substrate proteins. Drugs such as imatinib bind and block the catalytic domain and in doing so limit hematopoietic cell proliferation in CML patients. (b) and (c) modified from \[[@B75]\] and \[[@B76]\].](1741-7007-8-38-1){#F1}

![**Biology-driven cancer drug development for CML**. From the original description of CML in 1845, fundamental biology has driven the development of treatments for CML. Approximate times are shown for key events in the development of imatinib.](1741-7007-8-38-2){#F2}

Chronic myelogenous (or myeloid) leukemia (CML) was first identified in 1845 by Bennett and Virchow \[[@B9]\] and has been treated with a wide range of drugs \[[@B10]\]. In 1960, Nowell and Hungerford described a consistent chromosomal abnormality - the \'Philadelphia Chromosome\', named for the city in which they worked - in patients with CML \[[@B11]\]. This was later shown by Rowley to be formed from a reciprocal translocation of DNA between the long arms of chromosomes 9 and 22 \[[@B12]\] (Figure [1a](#F1){ref-type="fig"}).

In the 1970s and 1980s several oncogenes present in cancer-causing viruses were shown to have normal cellular equivalents that became altered in human cancers. For example, the Abelson murine leukemia retrovirus (A-MuLV) \[[@B13]\] was shown to carry a transforming gene (*vABL*) that had a normal cellular homolog, c*ABL*\[[@B14]\]. Subsequently, the *cABL*gene was shown to be involved in the chromosomal rearrangement in CML, translocating from chromosome 9 to the breakpoint cluster region (*BCR*) gene on chromosome 22 \[[@B15],[@B16]\] (Figure [1a](#F1){ref-type="fig"}). This results in the production of a fusion gene between *BCR*and *cABL*\[[@B17]\]. In 1981, *vABL*had been identified as a protein kinase \[[@B18]\] and the *BCR-ABL*fusion mRNA was later shown to encode a constitutively active kinase whose activity could transform cells both *in vitro*\[[@B19]\] and *in vivo*\[[@B20],[@B21]\]. Therefore, it was recognized that targeting the catalytic activity of ABL could potentially deliver a therapeutic window between tumor cells with constitutive activity of BCR-ABL and normal cells with more tightly controlled ABL activity. Subsequent studies on BCR-ABL biology have focused on defining the links between BCR-ABL activity and the pathological characteristics of CML and other diseases \[[@B22]\].

At the same time as the transforming activity of *BCR-ABL*had been established, several observations were made that, while not critical to understanding the biology of BCR-ABL and CML, were absolutely crucial to the eventual development of drugs used to treat the disease. First, it was recognized that certain small molecules could inhibit the activity of protein kinases \[[@B23]\]. Second, methods for expressing large amounts of active human proteins in insect cells were refined, allowing BCR-ABL protein to be generated to enable a drug development program \[[@B24]\]. Finally, antibody production technology had progressed to such a point that the activity of protein kinases could be monitored in a relatively robust manner. All of these factors enabled a team led by Matter at Ciba-Geigy to initiate a kinase small molecule inhibitor development program. By 1996, STI517 (imatinib) had been identified and its activity confirmed in BCR-ABL cells by Druker and colleagues \[[@B25]\]. In 1998, phase I clinical trials commenced \[[@B26]\], leading to drug approval by the US Food and Drug Administration in 2001.

At this time, the first resistance mechanisms to imatinib were identified \[[@B27]\]. These could have been due to mechanisms previously noted for chemotherapy resistance, such as enhanced metabolism or efflux of the drug from cells. However, in what turned out to be a general phenomenon, Sawyers and colleagues \[[@B27]\] identified BCR-ABL mutations in patients who had relapsed on imatinib treatment, which rendered the enzyme resistant to the inhibitory effects of imatinib \[[@B28]\]. The use of a three-dimensional structure of the catalytic domain of ABL in a complex with an imatinib variant \[[@B29]\] also gave insight into this phenomenon and has furthered our understanding of the mode of action of imatinib and the second-generation ABL inhibitors such as nilotinib \[[@B30]\] and dasatinib \[[@B31]\]. These latter drugs can overcome resistance caused by some, but importantly not all, BCR-ABL mutations. Very recently, allosteric inhibitors of ABL have been identified \[[@B32]\] (allosteric being shorthand for \'binding outside the catalytic site\'). These latter molecules bind the myristate binding site of ABL, as opposed to the ATP binding site targeted by imatinib and related inhibitors. This inhibitor-target interaction does however, induce a structural change in the catalytic domain of the kinase and this in turn inhibits the enzyme activity of ABL. When combined with imatinib, an ABL allosteric inhibitor can overcome resistance caused by BCR-ABL mutations such as T315I \[[@B32]\], illustrating the potential benefit of combining different modes of inhibition on the same target.

As a final note in the imatinib story, biological insight has been used to expand the range of patients that might be treated by this drug. As well as ABL, imatinib also inhibits related kinases, such as the cytokine receptor cKIT and platelet-derived growth factor receptors (PDGFRs). Constitutively active *cKIT*mutations are found in gastrointestinal stromal tumors and translocations in the *PDGFRB*gene are found in diseases such as chronic myelomonocytic leukemia (CMML). Imatinib has already shown considerable success for the treatment of gastrointestinal stromal tumors \[[@B33]\] and preliminary results suggest that it could also work in CMML characterized by *PDGFRB*alterations \[[@B34]\].

Similar successful approaches have resulted in the targeting of other oncogenes, such as epidermal growth factor receptor (*EGFR*; targeted by gefitinib and erlotinib, whose brand names are Iressa and Tarceva, respectively \[[@B35]\]) and Human epidermal growth factor receptor 2 (*HER2*; targeted by trastuzumab/Herceptin \[[@B36]\]). More recently, the targeting of oncogenic Hedgehog signaling in medulloblastoma and basal cell carcinoma \[[@B37],[@B38]\] has also shown considerable promise (Figure [3](#F3){ref-type="fig"}). *Hedgehog*(*hh*) was originally discovered by Nüsslein-Volhard and Wieschaus nearly 30 years ago as a \'segment polarity\' gene that controls *Drosophila*embryonic cuticle patterning \[[@B39]\]. Vertebrate orthologs of *hh*were identified in the early 1990s and subsequent studies have not only dissected the mechanisms underlying hedgehog signaling but have also shown Hedgehog to be involved in various aspects of animal development, from cell fate through to body length \[[@B40]\]. Importantly, Hedgehog signaling has been shown to be dysregulated in human cancers, notably gastrointestinal tumors, prostate cancer, hematological malignancies and gliomas. Recent clinical studies suggest that medulloblastomas and basal cell carcinomas that rely on Hedgehog signaling can be treated with a small molecule inhibitor that targets the *hh*signaling mediator, Smoothened \[[@B37],[@B38]\].

![**Targeting oncogenic Hedgehog signaling**. **(a)**In normal cells the Patched homolog, PTCH1, blocks the activation of the Smoothened homolog, SMO. Binding of Hedgehog ligand to PTCH1 removes the repression of SMO, and this drives transcriptional changes via the activity of GLI proteins. **(b)**In tumors such as basal-cell carcinoma and medulloblastoma, mutations in PTCH1 or SMO lead to constitutive, ligand-independent signaling and an addiction to hedgehog signaling. **(c)**Blocking the activity of SMO with a small molecule, GDC-0449 can ablate hedgehog signaling and thus inhibit cell growth in addicted tumor cells.](1741-7007-8-38-3){#F3}

Another notable advance in targeted therapy development has been in the development of small-molecule inhibitors of the oncogenic protein BRAF \[[@B41],[@B42]\]. The *BRAF*gene, a viral oncogene homolog that encodes a kinase involved in the RAS/RAF/MEK/ERK pathway (Figure [1b](#F1){ref-type="fig"}), is mutated in up to 70% of melanomas, with mutations such as *BRAF V600E*causing constitutive MEK/ERK activation. This MEK/ERK activation drives tumour cell proliferation and survival. Although there are various approaches designed to target RAS/RAF/MEK/ERK signaling \[[@B41]\], much effort has been placed in designing small-molecule BRAF inhibitors \[[@B42]\]. Clinical studies now suggest that targeting constitutively active BRAF in patients with melanomas or colorectal tumors characterized by V600E mutations can have significant clinical benefit \[[@B43]\] and, very recently, a detailed study of BRAF/RAS/CRAF signaling interactions has provided further insight into, and potential refinement of, this approach \[[@B44]\].

Of course, although targeted therapies are heralded as a considerable advance from standard chemotherapies, they are still affected by resistance and toxicity effects. Returning to imatinib, *BCR-ABL*mutations can drive resistance \[[@B27],[@B28]\], and moderate side effects of imatinib treatment, such as edema, do occur. However, with other targeted agents, such as sunitinib, toxicities such as a hand and foot skin reaction can be more severe and in fact dose-limiting. Some of these toxicities are likely to be caused by inhibition of the desired therapeutic target in normal tissues, whereas others may be due to the multi-kinase inhibition profile of some of the drugs used clinically. Nevertheless, targeted agents are generally well tolerated compared with chemotherapies and tend to deliver larger therapeutic windows.

In summary, in contrast to more traditional cancer therapies, the development, clinical use and refinement of imatinib and other targeted therapies could not have occurred without the considerable groundwork of biologists from many different disciplines. Nevertheless, putting this together required the vision and application of individuals willing to apply these developments.

The future of cancer research?
==============================

We do need to recognize and applaud the progress that has been made in biologically targeted therapeutic development. This is a great validation of the role of biological insight, but how this field might develop in the future is less clear. To frame this discussion, it is worth noting some of the key problems currently faced in cancer therapy.

First, there are some effective drugs but they are not used in an optimal manner. For some cancer types, there are a series of drugs that work relatively well but the response to them is very heterogeneous. We need to understand the reasons for this heterogeneity and tailor the right treatment to the individual patient, rather than finding the best for the average patient. Second, more often than not, even after an initial response, patients frequently relapse - we need a clearer understanding of the mechanisms underlying relapse and drug resistance if we are to overcome them. Third, for some cancer types, there are no really effective therapies and we need to identify new drug targets and develop methods of exploiting them. And finally, with the exception of a minority of cancers, preventative strategies are not available.

A fair assessment of the situation would be that we are a considerable way off from solving these problems. Understanding more about the biology of cancer will be key if we are to make significant advances. But we do need to go a step further; biologists need to be continually alert to the possibility of translating their findings into changing clinical practice. Several recent conceptual and experimental advances might help achieve this but, in short, all cancer biologists need to become, in part, \'translational\'.

A deeper understanding of the altered universe of the cancer cell
=================================================================

Understanding normal cell behavior has been a significant goal of modern biology and of course this is extremely important in defining the neoplastic process. However, it is now widely recognized that this is not enough in itself as there are a constellation of changes in the altered and forever adapting universe of the cancer cell. Hanahan and Weinberg \[[@B45]\] summarized an immense body of work by listing the \'hallmarks\' of cancer cells and tumors - a limitless replicative potential, resistance to apoptosis, insensitivity to anti-growth signals, self-sufficiency in growth signals, tissue invasion and metastasis, and sustained angiogenesis. Building on this model and our deeper understanding of cancer biology, Luo, Solimini and Elledge \[[@B46]\] have proposed additional characteristics, such as: evading immune surveillance \[[@B47]\]; an elevated DNA damage/replication response caused by elevated replication rates and also DNA repair defects in tumor cells \[[@B48]\]; proteotoxic stress - an increase in the amount of toxic, unfolded proteins in tumor cells and the resultant heat shock protein response \[[@B49]\]; mitotic stress/chromosomal instability \[[@B50]\]; metabolic stress - the increased use of glycolysis rather than oxidative phosphorylation as a means of producing ATP \[[@B51]\]; and oxidative stress - an increase in the level of reactive oxygen species in tumor cells \[[@B52]\].

The obvious translational output of defining these characteristics is in identifying additional means by which tumor cells can be targeted. For example, the renewed interest in cancer cell metabolomics and metabolic stress \[[@B53]\] will most likely lead to therapies that target tumor-specific reliances on particular aspects of glucose metabolism. Furthermore, the classification of these characteristics presents significant new opportunities for reinvention of the combination therapy paradigm for cancer therapy. Combinatorial targeting of different \'hallmarks\' of cancer with targeted therapies (Figure [4](#F4){ref-type="fig"}) could elicit an enhanced and durable therapeutic response, as is seen with combinations of classical chemotherapies.

![**Hallmarks of cancer**. The dissection of cancer biology has allowed the characteristics of tumor cells to be more accurately detailed. Drug classes targeting each of the characteristics are also shown (outside ring). Adapted from \[[@B46]\].](1741-7007-8-38-4){#F4}

Embracing the complexity of the cancer cell
===========================================

The control of cell growth and behavior has long been recognized to be complex. However, we are increasingly daunted by exactly how great a challenge it will be to understand or predict normal cell behavior or the rewiring that goes on in cancer cells. There are some recent examples in which the discovery of entire levels of cellular regulation, such as microRNAs, add yet another layer of complexity.

Moreover, our restricted and naive view of biology has meant that, in general, understanding cell behavior has been by studying discrete pathways. These pathways are often a misleading oversimplification of the complex molecular networks that control cell behaviour. However, help may be at hand in addressing this complexity in \'systems\' approaches. Although still in their infancy, these computational approaches coupled with deep transcriptomic, genomic proteomic or metabolic profiling promise an integrated approach and, with this, a better understanding of interacting molecular networks. This should allow us to start thinking seriously about how drugs perturb networks rather than discrete pathways and use this information to develop new \'network\' therapeutic strategies.

A significant challenge in cancer drug development, \'drugging the undruggable\', is being addressed by exploiting molecular networks. An example has been the use of poly(ADP-ribose) polymerase (PARP) inhibitors to treat BRCA-deficient cancers. *BRCA1*and *BRCA2*are both classical tumor suppressor genes: loss-of-function mutations disable BRCA1 and BRCA2 proteins and strongly predispose to cancer. Targeting tumor suppressor genes presents a particular problem: unlike gain-of-function oncogenic events such as the *BCR-ABL*fusion, it is not obvious how to pharmacologically target a tumor suppressor protein that is dysfunctional or even completely absent. However, exploiting knowledge of molecular networks may be of significant benefit here. In 2005, we demonstrated that tumor cells with deficiencies in either the *BRCA1*or *BRCA2*tumor suppressor genes are over 1,000 times more sensitive to potent inhibitors of the DNA repair protein PARP \[[@B54]\]. Underlying these observations is a network of synthetically lethal genes (Figure [5a](#F5){ref-type="fig"}).

![**A synthetic lethal network exploited in cancer treatment**. **(a)**Two genes or proteins are synthetically lethal when inactivation of either gene/protein is still compatible with cellular viability but inactivation of both leads to cell death \[[@B55]\]. Often synthetic lethal relationships represent networks of proteins that show a form of functional buffering. **(b)**A model for synthetic lethality using PARP inhibitors \[[@B54]\]. DNA is constantly damaged, both by environmental and by normal physiological processes. One of the more common forms of DNA damage is the formation of DNA single strand breaks (SSBs; step 1). SSBs are normally rapidly repaired by a process known as base excision repair (BER). BER is instigated by the activity of the poly(ADP ribose) polymerase, PARP1, and when PARP1 is inhibited (an example PARP inhibitor is shown), SSBs persist (step 2). As cells enter S phase, and DNA is replicated; replication forks are eventually stalled by persistent SSBs (step 3; the direction of a replication fork is shown by the green arrow). If not rapidly repaired, stalled replication forks can often degenerate and form DNA double strand breaks (DSBs), which are highly likely to be lethal (step 4). In normal cells, an additional DNA repair process, homologous recombination (HR), can repair stalled replication forks and DSBs (step 5). HR is mediated by BRCA1 and BRCA2 and acts as a functional buffer to enable normal cells to survive the effects of PARP and BER inhibition. Conversely, in patients with germ-line *BRCA*gene mutations, tumor cells show a severe HR defect (step 6). PARP inhibition combined with HR deficiency leads to tumor cell death either driven by the formation of lethal DSBs or because mutagenic forms of repair predominate in the absence of HR. The genomic instability that follows the use of these non-HR forms of DSB repair eventually limits the fitness and viability of tumor cells. **(c)**Synthetic lethality in *in vitro*cell culture. Clonogenic assays, which estimate tumor cell survival, demonstrate that tumor cells with either BRCA1 or BRCA2 deficiency are profoundly sensitive to potent PARP inhibitors such as KU0058948 (Kudos/AstraZeneca). Reproduced, with permission, from \[[@B54]\]. *In vitro*synthetic lethality translates into clinical synthetic lethality \[[@B56]\]. Computed tomographic (CT) scans of the abdomen in a patient with advanced ovarian cancer and *BRCA*mutation family history showed a reduction in the size of a peritoneal tumor nodule by 66% over a 4-month treatment period during which she received a potent PARP1 inhibitor, olaparib, at a dose of 100 mg, twice daily, for 2 of every 3 weeks. CT scans of the abdomen in another patient with advanced ovarian cancer, who had a *BRCA1*mutation (4693delAA), showed complete regression of a peritoneal tumor nodule over a 4-month treatment period with olaparib (200 mg, twice daily) for a year.](1741-7007-8-38-5){#F5}

Two genes or proteins are synthetically lethal when inactivation of either gene/protein is still compatible with cellular viability but inactivation of both leads to cell death \[[@B55]\]. Often, synthetic lethal relationships represent networks of proteins that show a form of functional buffering, and this seems to be the case with BRCA proteins and PARP. PARP is involved in the repair of DNA breaks in a single strand of DNA. In normal cells, PARP inhibition and the resultant increase in DNA single strand breaks is functionally compensated for by a second form of DNA repair, homologous recombination. Homologous recombination is controlled by BRCA1 and BRCA2 - when BRCA proteins are defective, as is the case in tumors from breast, ovarian and prostate cancer patients carrying germline *BRCA*gene mutations, this functional buffering is lost, and cells become exquisitely sensitive to PARP inhibitors (Figure [5b, c](#F5){ref-type="fig"}). These original in vitro observations have been translated into clinical trials and early results suggest significant tumor responses accompanied by relatively mild side effects when compared with standard chemotherapies \[[@B56]\]. This suggests that the large therapeutic window observed in the laboratory may indeed translate into the clinic. Although expanded clinical trials are needed to prove that such synthetic lethal approaches really do deliver larger therapeutic windows, the preliminary indications are that exploiting molecular networks may be a viable approach.

As discussed above, a large amount of effort has also been invested in targeting oncogenes as therapeutic targets. It is thought that tumor cells can be \'addicted\' to the activity of an oncogene \[[@B57]\], such that once the oncogene activity (or the pathway it controls) is blocked, tumor cells can no longer survive. Therefore, if one can identify an activated oncogene that a tumor cell is addicted to, there is the possibility of therapeutic approach to inhibit it. However, a significant problem arises if the target is not particularly suited to pharmacological inhibition. For example, a significant number of tumors are driven by either *MYC*or *RAS*oncogenes, but as transcription factors and GTPases, respectively, these proteins have been difficult to target, compared with, for example, protein kinases such as BCR-ABL.

One solution is to exploit molecular networks; the activity of oncogenes such as *MYC*or *RAS*results in considerable adaptive rewiring of cellular networks and tumor cells may become \'addicted\' to these changes. These \'non-oncogene addictions\' \[[@B46]\] could be therapeutically targeted. By performing high-throughput loss-of-function genetic screens that exploit RNA interference technology \[[@B58]\], Gilliland and colleagues \[[@B59]\] showed that tumor cells with mutant *RAS*have acquired a dependence on the kinase STK33; tumor cell molecular networks have been rewired such that STK33 now becomes critical whereas it is not in normal cells. Studies by Elledge and colleagues \[[@B60]\] and Hahn and colleagues \[[@B61]\] have also identified additional addictive effects in tumor cells that depend on RAS activity and similar work has elicited targets for MYC-driven cancers \[[@B62]\]. Whether these effects can ultimately be exploited therapeutically remains to be seen, but these proof-of-principle experiments clearly highlight the potential for network targeting.

Akin to the approach of exploiting the complexity of cancer cells, the integration of multiple data types is also now proving a powerful tool to identify novel cancer drug targets. This is proving particularly true when functional genomic screens, such as those using RNA interference, are combined with molecular profiling techniques. For example, Hahn and colleagues recently screened a small panel of colorectal tumor cell lines with an RNA interference library to identify *CDK8*, a gene that not only controlled tumor cell viability but also modulated WNT signaling, an oncogenic pathway commonly active in colorectal cancer \[[@B63]\]. By integrating these screen data with the genetic profiles of colorectal adenocarcinomas, they demonstrated that the *CDK8*gene was also amplified in a significant proportion of colorectal tumors, suggesting that it could be a promising drug target. Furthermore, the *CDK8*gene copy alteration could also serve as a biomarker with which to select patients for treatment with a CDK8 targeting agent, once developed. Similar studies have also used the integration of a wide variety of disparate data types, such as gene expression profiles, immunohistochemical profiles, metabolic profiles and forms of functional analysis, to identify novel cancer drug targets \[[@B64],[@B65]\]. With the availability of technology, such as next generation sequencing, that offers the rapid dissection of cancer genome and transcriptome sequences \[[@B66]-[@B70]\], these integrated approaches are likely to become commonplace.

These next generation profiling technologies may also allow us to further our understanding of intra- and inter-tumor heterogeneity. It is well established that tumors from patients with diseases that are similar in clinical presentation are often distinct at the molecular level (for example, in terms of the transcriptomic profile or genomic content). Furthermore, heterogeneity also exists between primary and metastatic lesions from the same patient and also within individual tumors. It is likely that this heterogeneity explains, in part at least, differing responses to therapy between ostensibly similar tumors. One approach to understanding this heterogeneity is to first catalog it, and much effort has already gone into the characterization of tumor heterogeneity at the genomic and transcriptomic levels, with a seminal example being the gene expression profiling of 65 breast tumors \[[@B71]\].

With the advent of next generation sequencing we are now seeing the first reports of base-pair resolution DNA sequences of human tumors \[[@B68],[@B69]\]. This trickle will turn into a torrent as the cost of these profiling approaches falls, allowing us to properly address heterogeneity and to further tailor treatment to the individual. Nevertheless, the first few tumor genome DNA sequences are already informing our understanding of cancer biology and hinting at therapeutic approaches. For example, the partial DNA sequence of a range of breast tumors and tumor cell lines already suggests that particular DNA repair defects are present, as represented by the specific patterns of DNA deletion and rearrangement that are left behind as footprints in the tumor genome \[[@B69]\]. Similarly, the type and number of mutations found in the genome sequences of a melanoma cell line and a lung tumor cell line \[[@B68],[@B69]\] seem to reflect the environmental agents (exposure to ultraviolet light and tobacco use, respectively) that initially fostered tumorigenesis. Such base-pair resolution DNA sequences could be used as diagnostics to identify, for example, specific DNA repair defects and to select therapies accordingly. Similar advances in proteomic \[[@B72]\] and also metabolic \[[@B73]\] profiling could also address heterogeneity and inform therapeutic development. It is of course implicit that with this wealth of biological data, we need to make advances in our ability to process and analyze such large data collections.

Biology-driven cancer drug development
======================================

Returning to the here-and-now, there are several organizational and logistical roadblocks to the application of basic research in cancer therapeutic development that have made this avenue daunting to many biologists. The first is understanding and recognizing the actual clinical issues. This means that interactions with clinicians who understand the benefits of basic research need to be fostered and a meaningful dialog established that overcomes the sometimes arcane jargon used in each field. Access to tumor tissue has also been a problem and the role of the pathologist is critical here. Pathologists, especially the new generation of molecular pathologists, can also provide the pivotal link between basic and clinical research. Finally, applied translational research has frequently been seen as inferior to \'pure\' basic research. With the application of cutting edge technology and fundamental biological principles to translational research, it\'s clear that addressing clinical realities is as pure a science as any.

Increasingly, biology needs to have a strong role in the design and analysis of clinical trials. It is generally accepted that targeted cancer drugs cannot be used on a \'one size fits all\' model and trials need to reflect the original fundamental biology. This means designing trials with solid pre-clinical laboratory work and where the patient subgroup to be treated is refined according to precise biomarkers, such as specific oncogene mutations. We argue elsewhere (AA and JS DeBono, unpublished work) that biomarkers for drug efficacy and patient selection need to be developed and integrated very early in the clinical trials process, such as in phase 1. Again, this means that biologists need to work closely with clinicians as drugs are developed, which in the past has been highly unusual. Likewise, studying cancers in the neo-adjuvant context (before definitive surgery) or in short \'window of opportunity\' studies (where a therapy is administered and its molecular consequences closely followed using biopsies over a relatively short period of time or \'window\') provides a wealth of material for the biologist to study drug responses in real tumors *in situ*. Finally, at least in the advanced cancer setting, resistance is at present almost inevitable, and the ability to obtain and study metastatic biopsies will be critical in understanding these mechanisms. Moreover, this will allow testing of hypotheses developed in cell line or animal models of drug resistance in the genuine clinical context \[[@B74]\].

Most cancer drug development is now biology driven. However, to ensure that fundamental new insights into the biology of cancer are used, it is essential that integrated approaches are used. This operates both at the level of the experimental approaches, taking full account of the complexity of cancer, but also at the level of interaction of different disciplines. Although the trend will be towards \'big\' science, there is still an important role for the biologist in proving insight from hypothesis-based approaches as long as this is applied appropriately. A large number of significant challenges in cancer remain, such as the relentless plasticity of the cancer genome and the Darwinian selection of resistance that results. However, with a true concord between biologists, oncologists, pharmaceutical companies and patients we believe that what we all want can be achieved: effective treatments for cancer.
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